<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02366481</url>
  </required_header>
  <id_info>
    <org_study_id>620511</org_study_id>
    <nct_id>NCT02366481</nct_id>
  </id_info>
  <brief_title>Vitamin K and Glucose Metabolism in Adults at Risk for Diabetes (Vita-K 'n' Adults Study)</brief_title>
  <official_title>Vitamin K and Glucose Metabolism in Adults at Risk for Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Augusta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tufts University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nattopharma ASA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Augusta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Given that glutamate carboxylation or decarboxylation is key to the metabolic role of
      osteocalcin (at least in mouse models) and that carboxylation is vitamin K dependent, it is
      critical to isolate the effect of vitamin K manipulation on carboxylation of osteocalcin and
      its subsequent effect on glucose metabolism in clinical trials. The purpose of this
      randomized, double-blind, placebo-controlled clinical trial in adults is to determine whether
      eight weeks of daily supplementation with vitamin K2 (menaquinone-7) can improve markers in
      blood associated with diabetes risk.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">December 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in insulin sensitivity</measure>
    <time_frame>Change from baseline in insulin sensitivity at 8 weeks</time_frame>
    <description>Insulin sensitivity will be calculated from plasma insulin and glucose concentrations measured during a 2-hour oral glucose tolerance test by using the oral glucose minimal model.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in beta-cell function</measure>
    <time_frame>Change from baseline in beta-cell function at 8 weeks</time_frame>
    <description>Beta-cell function, as assessed by dynamic beta-cell responsitivity, will be calculated from plasma glucose and C-peptide concentrations measured during a 2-hour oral glucose tolerance test by using the oral C-peptide minimal model.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in prothrombin time (PT)</measure>
    <time_frame>Change from baseline in PT at 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in activated partial thromboplastin time (aPTT)</measure>
    <time_frame>Change from baseline in aPTT at 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in arterial stiffness (PWV)</measure>
    <time_frame>Change from baseline in arterial stiffness at 8 weeks</time_frame>
    <description>Arterial stiffness will be assessed using carotid-femoral pulse wave velocity (PWV) by applanation tonometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in endothelial function (FMD)</measure>
    <time_frame>Change from baseline in endothelial function at 8 weeks</time_frame>
    <description>Endothelial function will be assessed using brachial artery flow-mediated dilation (FMD) by ultrasound.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Obesity</condition>
  <condition>Insulin Resistance</condition>
  <condition>Insulin Sensitivity</condition>
  <condition>Beta-Cell Dysfunction</condition>
  <condition>Prediabetes</condition>
  <arm_group>
    <arm_group_label>Placebo-Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo-control group will take two placebo softgel capsules every day for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-Dose Vitamin K2 (90-mcg/d)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The low-dose vitamin K group will take one 90-mcg vitamin K2 (menaquinone-7) softgel capsule and one placebo softgel capsule every day for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-Dose Vitamin K2 (180-mcg/d)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The high-dose vitamin K group will take two 90-mcg vitamin K2 (menaquinone-7) softgel capsules every day for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Two placebo softgel capsules (containing no vitamin K2) every day for 8 weeks.</description>
    <arm_group_label>Placebo-Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Low-Dose Vitamin K2 Supplement (menaquinone-7; 90-mcg/d)</intervention_name>
    <description>One 90-mcg vitamin K2 softgel capsules (containing no vitamin K2) and one placebo softgel capsule everyday for 8 weeks.</description>
    <arm_group_label>Low-Dose Vitamin K2 (90-mcg/d)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>High-Dose Vitamin K2 Supplement (menaquinone-7; 180-mcg/d)</intervention_name>
    <description>Two 90-mcg vitamin K2 softgel capsules every day for 8 weeks.</description>
    <arm_group_label>High-Dose Vitamin K2 (180-mcg/d)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adults between 18 and 65 years old

          2. Subject understands the study protocol and agrees to comply with it

          3. Informed Consent Form signed by the subject

        Exclusion Criteria:

          1. Subjects using vitamin supplements containing vitamin k

          2. Subjects with (a history of) metabolic or gastrointestinal diseases including hepatic
             disorders

          3. Subjects presenting chronic degenerative and/or inflammatory diseases

          4. Subjects receiving systemic treatment or topical treatment likely to interfere with
             evaluation of the study parameters (salicylates, antibiotics)

          5. Subjects receiving corticosteroid treatment

          6. Subjects using oral anticoagulants

          7. Subjects with a history of soy allergy

          8. Subjects who have participated in a clinical study more recently than one month before
             the current study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norman K Pollock, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pediatrics, Medical College of Georgia, Augusta University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Norman K Pollock, Ph.D.</last_name>
    <phone>706-721-5424</phone>
    <email>npollock@augusta.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Celestine F Williams, M.S.</last_name>
    <phone>706-721-8553</phone>
    <email>cewilliams@augusta.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical College of Georgia; Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norman K Pollock, Ph.D.</last_name>
      <phone>706-721-5424</phone>
      <email>npollock@augusta.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pollock NK, Bernard PJ, Gower BA, Gundberg CM, Wenger K, Misra S, Bassali RW, Davis CL. Lower uncarboxylated osteocalcin concentrations in children with prediabetes is associated with beta-cell function. J Clin Endocrinol Metab. 2011 Jul;96(7):E1092-9. doi: 10.1210/jc.2010-2731. Epub 2011 Apr 20.</citation>
    <PMID>21508147</PMID>
  </reference>
  <reference>
    <citation>Gower BA, Pollock NK, Casazza K, Clemens TL, Goree LL, Granger WM. Associations of total and undercarboxylated osteocalcin with peripheral and hepatic insulin sensitivity and β-cell function in overweight adults. J Clin Endocrinol Metab. 2013 Jul;98(7):E1173-80. doi: 10.1210/jc.2013-1203. Epub 2013 Apr 24. Erratum in: J Clin Endocrinol Metab. 2016 May;101(5):2265.</citation>
    <PMID>23616149</PMID>
  </reference>
  <reference>
    <citation>Booth SL, Centi A, Smith SR, Gundberg C. The role of osteocalcin in human glucose metabolism: marker or mediator? Nat Rev Endocrinol. 2013 Jan;9(1):43-55. doi: 10.1038/nrendo.2012.201. Epub 2012 Nov 13. Review.</citation>
    <PMID>23147574</PMID>
  </reference>
  <reference>
    <citation>Pollock NK. Childhood obesity, bone development, and cardiometabolic risk factors. Mol Cell Endocrinol. 2015 Jul 15;410:52-63. doi: 10.1016/j.mce.2015.03.016. Epub 2015 Mar 27. Review.</citation>
    <PMID>25817542</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2015</study_first_submitted>
  <study_first_submitted_qc>February 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2015</study_first_posted>
  <last_update_submitted>March 25, 2018</last_update_submitted>
  <last_update_submitted_qc>March 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Augusta University</investigator_affiliation>
    <investigator_full_name>Norman Pollock</investigator_full_name>
    <investigator_title>Associate Professor, Department of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Vitamin K</keyword>
  <keyword>Vitamin K2</keyword>
  <keyword>Menaquinone-7</keyword>
  <keyword>Osteocalcin</keyword>
  <keyword>Adults</keyword>
  <keyword>Obesity</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Insulin sensitivity</keyword>
  <keyword>Beta-cell function</keyword>
  <keyword>Prediabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Vitamin K 2</mesh_term>
    <mesh_term>Vitamin MK 7</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

